Cur síos ar an tionscadal
Circular approach to respiratory disease patients, e.g. asthma and COVID, allowing diagnosis and management in a simple, safe and cost-effective way combining Breathomics and Artificial Intelligence.
evernoa helps healthcare professionals, to diagnose and monitor the illness, and patients, providing them objective information to play and active and self-determining role in self-managing their condition. Composed by a suite of POC devices: PRO, high-precision needed in severe cases, PLUS for mild-moderate (both for professional use) and HOME a low-cost device for patient homecare and telemonitoring, connected to a SW platform that processes and shows data to establish personalized attention.
MSc in Biomedical Engineering with Outstanding final achievement, UPNA
Master’s Degree, Telecommunication Engineering with Honours, UPNA.
Master’s Degree, Industrial Engineering, ESIEE Paris.
Languages Spanish, English and French
Experience .Manager of the R&D+i Department of the company AH Asociados (6 years). Deep knowledge in Regulatory affairs and Quality Assurance She has led implementations for ICT solutions in the healthcare sector, from the design through to implementation stages for the healthcare system. Technical & Financial management of R&D+i European projects (H2020 program), trans-regional projects (MANUNET and LEAD ERA program) and regional projects (Government of Navarra).
An Spáinn [Comunidad Foral de Navarra]
Costas measta an tionscadail
EUR 1.5 milliún
Tionscal le haghaidh FBManna agus gnólachtaí meánchaipitlithe
Úinéireacht na sócmhainní
An cineál tionscadail
Stádas an tionscadail
An cineál ioncaim
Bunaithe ar an margadh
Cruthú post tuartha
Cur i láthair tráchtála
Réasúnú eacnamaíoch / Samhail ghnó
Eversens business model is a “bait and hook” model, devices are offered at an affordable price, but the selling of sensor cartridges, consumables for the device and SW licences app fees will generate recurrent income. Standard version of evernoa SW is free of charge to be used by PRO and PLUS customers but a premium licence with further functionalities will be offered. HOME will be sold first to pharmacies in a first stage by and directly patients in a second stage through our own e-commerce with a e-Health SaaS strategy
Our economic and commercial feasibility is based on a solid market research combining expert reports and field information provided by our distributors. AMR, for instance, estimates a growth of 54.5% annually for the Intelligent Asthma Monitoring market.
We have identified worldwide potential distributors for evernoa, and we are now negotiating agreements with nine of them to market it. They have shown their enthusiasm about the evernoa sales potential (see LoIs).
Innovations included in evernoa devices (extended analysis in PRO, combined measurement of CO in PLUS and intended use including patients of HOME) are totally disruptive so we envisage blue ocean market.
Mionsonraí an mhaoinithe
Maoiniú tionscadail a aimsíodh: EUR 0.22 milliún (15 %)
Foinse maoinithe: Príobháideach
Eversens requires €1.5 Million to develop evernoa project mainly TRL7-8 activities for commercial and TRL9-related activities. We propose the following financing structure 1.20 equity and 0.3 bank loans.Regarding Exit Strategy, Eversens is totally open to consider different possibilities: (1) Another investor acquires shares. Eversens consider this is the most probable exit (2) Going public (3)Treasury stock: Eversens, by means of generated cash-flow, re-acquires shares.
Baic fhéideartha/ Rioscaí féideartha
We provide a description of the risk (I: impact, P: Probability, M:MEDIUM L:LOW, H. HIGH)followed by the proposed risk-mitigation measures. Inconclusive results artificial intelligence. M I–L P. Leading experienced organisation collaboration. No win-win distribution agreements. H I–L P. Use current network to expand their products catalogue. Cooperation with experts in medtech and market access consultancy. Different purchasing process L I-H P. Flexible business model offering either the sell
Eolas breise faoin tionscadal
All evernoa devices are covered by our patents and industrial design models. All our marks are registered. Our devices are under the scope of the Directive 98/79/EC so self-certification is the certification path reaching market in less time. Transition to Regulation 2017/746 will be gradually implemented. Evernoa HOME will launched to be used by pharmacist and then to patients ( nonprofessional users).evernoa BASE, which is the precursor of the evernoa SYSTEM was launched in the ERS congress in 2019 and currently it is sold in Spain, Italy, France, Germany and Switzerland. We are now negotiating agreements with 8 additional distributors .Eversens has currently nine highly qualified workers.
Ní thugann an Coimisiún aon bharánta ná ní dhéanann aon uiríoll, cibé acu go follasach nó go hintuigthe é, go bhfuil an Fhaisnéis Tionscadail saor ó earráidí. Cuirtear an Fhaisnéis Tionscadail ar fáil gan aon ghealltanais, coinníollacha nó barántaí i dtaobh chruinneas na faisnéise sin.
A free translation into English has been provided by the European Commission on this project, for information purposes only. The original language version is the authentic version.